Literature DB >> 3400604

Mechanism of mitral valve area increase by in vitro single and double balloon mitral valvotomy.

P A Ribeiro1, M al Zaibag, V Rajendran, A Ashmeg, S al Kasab, Y al Faraidi, M Halim, M Idris, M R al Fagih.   

Abstract

The mechanism of mitral valve area increase by double balloon mitral valvotomy in vitro has not been defined, nor have the mitral valve area results achieved by single versus double balloon mitral valvotomy technique been compared. After a selection of 29 intact mitral valves excised at cardiac surgery from patients with a mitral valve area less than or equal to 1.5 cm2 was made, double balloon mitral valvotomy was attempted in 14 valves using two 20-mm diameter balloon catheters (group 1) and single balloon mitral valvotomy using a 20-mm balloon was undertaken in 15 valves (group 2). In group 1 the mitral valve area increased from 0.9 +/- 0.03 to 1.9 +/- 0.05 cm2 (mean +/- standard error of the mean) (p less than 0.001), with a mean anterior commissural split of 5.3 +/- 0.2 mm and a posterior split of 4.1 +/- 0.2 mm. Following single balloon valvotomy (group 2), the mean mitral valve area increased from 0.8 +/- 0.03 to 1.2 +/- 0.03 cm2 (p less than 0.001), with the mean anterior commissural split being 2.6 +/- 0.2 mm and the posterior 2.1 +/- 0.2 mm. Ten mitral valves from group 2 underwent a second dilatation using the double balloon technique and the mitral valve area increased further from 1.2 +/- 0.06 to 1.9 +/- 0.06 cm2 (p less than 0.001). Overall, commissural splitting occurred preferentially in calcified commissures (81%), as opposed to only 56% of noncalcified commissures. Commissural splitting is the manner in which mitral valve area increases after double balloon mitral valvotomy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1988        PMID: 3400604     DOI: 10.1016/0002-9149(88)90223-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Contemporary criteria for the selection of patients for percutaneous balloon mitral valvuloplasty.

Authors:  B D Prendergast; T R D Shaw; B Iung; A Vahanian; D B Northridge
Journal:  Heart       Date:  2002-05       Impact factor: 5.994

2.  In vitro balloon dilatation of mitral valve stenosis: the importance of subvalvar involvement as a cause of mitral valve insufficiency.

Authors:  A S Sadee; A E Becker
Journal:  Br Heart J       Date:  1991-05

3.  Balloon dilatation of the mitral valve by a single bifoil (2 x 19 mm) or trefoil (3 x 15 mm) catheter.

Authors:  J Patel; S Vythilingum; A S Mitha
Journal:  Br Heart J       Date:  1990-11

4.  The role of three dimensional transesophageal echocardiography novel-score in the success of redo percutaneous balloon mitral valvuloplasty.

Authors:  Kadriye Memic Sancar; Gamze Babur Guler; Halil Ibrahim Tanboga; Ali Riza Demir; Ahmet Anil Sahin; Omer Tasbulak; Seda Tukenmez Karakurt; Tugba Aktemur; Yalcın Avci; Umit Bulut; Meltem Tekin; Ekrem Guler; Ali Kemal Kalkan; Mehmet Erturk
Journal:  Int J Cardiovasc Imaging       Date:  2021-10-24       Impact factor: 2.357

5.  Balloon mitral valvuloplasty: clinical experience at the Texas Heart Institute.

Authors:  P A Tucker; J J Ferguson; M Harlan; C M Gaos; A Massumi
Journal:  Tex Heart Inst J       Date:  1992

6.  Echocardiographic assessment before and after Percutaneous Transvenous Mitral Commissurotomy in patients with Rheumatic Mitral Stenosis.

Authors:  Adnan Khan; Ihtesham Shafiq; Muneeb Jan; Zair Hassan
Journal:  Pak J Med Sci       Date:  2021 Jan-Feb       Impact factor: 1.088

7.  Echocardiographic assessment of mitral valve morphology after Percutaneous Transvenous Mitral Commissurotomy (PTMC).

Authors:  Hosam Hasan-Ali; Hamdy Shams-Eddin; Alaa A Abd-Elsayed; Muhammad H Maghraby
Journal:  Cardiovasc Ultrasound       Date:  2007-12-08       Impact factor: 2.062

8.  Percutaneous transmitral balloon commissurotomy using a single balloon with arteriovenous loop stabilisation: an alternative when there is no Inoue balloon.

Authors:  Endale Tefera; Mohamed Leye; Patrick Garceau; Denis Bouchard; Joaquim Miró
Journal:  Cardiovasc J Afr       Date:  2018-02-19       Impact factor: 1.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.